Abbas S et al (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116(12):2122–2126

Article  CAS  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A et al (2017) Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget 8:89566–89579

Article  PubMed  PubMed Central  Google Scholar 

Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11:1–12

Article  Google Scholar 

Arnold HK, Sears RC (2006) Protein phosphatase 2A regulatory subunit B56alpha associates with c-Myc and negatively regulates c-Myc accumulation. Mol Cell Biol 26:2832–2844

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen CT, Wang PP, Mo WJ, Zhang YP, Zhou W, Deng TF et al (2019) Expression profile analysis of prognostic long non-coding RNA in adult acute myeloid leukemia by weighted gene co-expression network analysis (WGCNA). J Cancer 10(19):4707–4718

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cicenas J, Zalyte E, Bairoch A, Gaudet P (2018) Kinases and cancer. Cancers 10:1–7

Google Scholar 

Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D et al (2016) TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44:1–11

Article  Google Scholar 

De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K et al (2011) EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol 154(3):337–348

Article  PubMed  Google Scholar 

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS et al (2018) Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. New Engl J Med 378(25):2386–2398

Article  CAS  PubMed  Google Scholar 

Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152

Article  PubMed  Google Scholar 

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

Article  PubMed  PubMed Central  Google Scholar 

De Weer AN, Mestdagh P, Preter KD, Meulen JVD, SpelemanF (2009) Downregulation of MiR-449a is essential for the survival of EVI1 positive leukemic cells through modulation of NOTCH1 and BCL2. Blood 114(22):361

Enjeti AK, Angel D’C, Melville K, Verrills NM, Rowlings P, (2016) A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. Anti-Cancer Drugs 27:560–568

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng Y, Feng F, Pan S, Zhang J, Li W (2023) Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt/mTOR/NF-κB signaling, 13. Brain Behav (4):e2965

Ferret-Sena V, Capela C, Macedo A, Salgado AV, Derudas B, Staels B et al (2022) Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis. Front Mol Neurosci 15:1077381

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O’Farrell AM, Bello CL et al (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3):986–993

Article  CAS  PubMed  Google Scholar 

Fiedler W, Kayser S, Kebenko M, Krauter J, Schlenk RF (2012) Sunitinib and intensive chemotherapy in patients with acute myeloid leukemia and activating FLT3 mutations: results of the AMLSG 10-07 study (ClinicalTrials.gov No. NCT00783653). Blood 120(21):1483

Garcia JS, Stone R (2017) The development of FLT3 inhibitors in acute myeloid leukemia. Hematol Clin North Am 31(4):663–680

Article  Google Scholar 

Gehring JS, Fischer B, Lawrence M, Huber W (2015) SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31:3673–3675

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grimwade D, Mrozek K (2011) Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol-Oncol Clin North Am 25(6):1135–1161

Article  PubMed  Google Scholar 

Handschuh L (2019) Not only mutations matter: molecular picture of acute myeloid leukemia emerging from transcriptome studies. J Oncol 2019:1–36

Article  Google Scholar 

Hartmann L, Metzeler KH (2019) Clonal hematopoiesis and preleukemia—genetics, biology, and clinical implications. Genes Chromosomes Canc 58:828–838

Article  CAS  Google Scholar 

Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R et al (2012) VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J Med Chem 55(2):725–734

Article  CAS  PubMed  Google Scholar 

Huang H, Chen F, Chou W, Hou H, Ko B, Lin C et al (2019) Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer 19:1–14

Article  Google Scholar 

Huang W, Zheng S, Wang Q, Zhao N, Long Z (2023) Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia. Sci Rep 13(1):15658

Article  CAS  PubMed  PubMed Central  Google Scholar 

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE et al (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28(9):1774–1783

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janssens V, Goris J, Hoof CV (2005) PP2A: the expected tumorsuppressor. Curr Opin Genet Dev 15:34–41

Article  CAS  PubMed  Google Scholar 

Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS (2018) Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book 38:555–573

Article  PubMed  Google Scholar 

Levis M (2013) FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program 2013:220–226

Article  PubMed  Google Scholar 

Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074

Article  PubMed  Google Scholar 

Li X, Xu L (2023) Exploring prognostic markers for patients with acute myeloid leukemia based on cuproptosis related genes. Transl Cancer Res 12(8):2008–2022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S et al (2012) miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 3:1–13

Article  Google Scholar 

Li X, Qi J, Song X, Xu X, Pan T, Wang H et al (2022) DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia. Exp Hematol Oncol 11(1):74

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lindblad O, Chougule R, Moharram SA, Kabir NN, Sun J, Kazi JU et al (2015) The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochem Bioph Res Co 467:742–747

Article  CAS  Google Scholar 

Liu Y, Cao Y, Yang X, Chen H, Yang H, Liu Y et al (2023) High ex